Wakefield Asset Management Lllp Gilead Sciences, Inc. Transaction History

Wakefield Asset Management Lllp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	BUY	$77.31 - $88.08 $13,915 - $15,854	180 Added 0.52%	34,548 $2.87 Million
Q4 2022 Jan 30, 2023	BUY	$62.32 - $89.47 $1.81 Million - $2.6 Million	29,099 Added 552.27%	34,368 $2.95 Million
Q3 2022 Nov 07, 2022	SELL	$59.54 - $68.01 $3,691 - $4,216	-62 Reduced 1.16%	5,269 $325,000
Q2 2022 Aug 09, 2022	BUY	$57.72 - $65.01 $307,705 - $346,568	5,331 New	5,331 $330,000
Q4 2019 Jan 27, 2020	SELL	$61.62 - $67.78 $196,013 - $215,608	-3,181 Closed	0 $0
Q3 2019 Oct 25, 2019	SELL	$62.51 - $69.0 $5,938 - $6,555	-95 Reduced 2.9%	3,181 $202,000
Q2 2019 Aug 13, 2019	BUY	$61.87 - $69.38 $202,686 - $227,288	3,276 New	3,276 $221,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Wakefield Asset Management Lllp, based on Form 13F filings with the SEC.

Stay updated on Wakefield Asset Management Lllp with notifications on news.